A new immunomodulator imunorix: pathogenetic rationale for the application of imunorix in ARI in frequently sick children

The goal of the study was to assess therapeutic efficacy, tolerance and safety of «Imunoriks» in randomized controlled study This drug was used as an immunostimulant in complex treatment for acute respiratory diseases in 60 children at the age from 3 to 14 years, who suffer frequently and durably and had acute (or recurrent) laryngotracheobronchitis against the background of ARVI with concomitant infectious and physical abnormality. The children were allocated in test and control groups each comprising three persons by random indication.